Pipamazine

Pipamazine

SCHEMBL49665

NC(=O)C1CCN(CCCN2c3ccccc3Sc3ccc(Cl)cc32)CC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 7/20 1.00
HRH1 P35367 7/20 1.00
DRD3 P35462 7/20 1.00
CYP2D6 P10635 7/20 1.00
SLC6A2 P23975 6/20 1.00
SLC6A4 P31645 6/20 1.00
ADRA2B P18089 5/20 1.00
ADRA2C P18825 5/20 1.00
HTR2A P28223 5/20 1.00
HTR2B P41595 5/20 1.00
ADRA2A P08913 5/20 1.00
HTR2C P28335 4/20 1.00
DRD1 P21728 4/20 1.00
CHRM5 P08912 2/20 1.00
ADRA1D P25100 2/20 1.00
HTR6 P50406 2/20 1.00
SIGMAR1 Q99720 2/20 1.00
MAPK1 P28482 5/20 0.69
LMNA P02545 5/20 0.69
HTR1A P08908 5/20 0.69

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pipamazine SCHEMBL30627529 1.00 DRD2 (1.00) DRD2HRH1DRD3CYP2D6SLC6A2
Pipamazine SCHEMBL30307637 1.00 DRD2 (1.00) DRD2HRH1DRD3CYP2D6SLC6A2
Pipamazine SCHEMBL26628959 1.00 DRD2 (1.00) DRD2HRH1DRD3CYP2D6SLC6A2
SCHEMBL14437190 0.85 CYP2D6 (0.74) DRD2HRH1DRD3CYP2D6SLC6A2
SCHEMBL23898817 0.85 DRD2 (0.74) DRD2HRH1DRD3CYP2D6SLC6A2
SCHEMBL11743885 0.85 DRD2 (0.73) DRD2HRH1DRD3CYP2D6SLC6A2
Metopimazine SCHEMBL29462317 0.84 DRD3 (1.00) DRD2HRH1DRD3CYP2D6SLC6A2
Metopimazine SCHEMBL30038347 0.84 DRD3 (1.00) DRD2HRH1DRD3CYP2D6SLC6A2
SCHEMBL23921987 0.84 HRH1 (0.73) DRD2HRH1DRD3CYP2D6SLC6A2
Metopimazine SCHEMBL49905 0.84 DRD3 (1.00) DRD2HRH1DRD3CYP2D6SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 2558 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4525870-A1 METHODS OF TREATING CUSHING'S SYNDROME AND LIVER DISORDERS, AND OF REDUCING LIVER TOXICITY OF OTHER DRUGS ADMINISTERED TO A PATIENT Corcept Therapeutics Incorporated (US) 2025-03-26 EP claimed
CN-119317433-A Methods for treating cushing's syndrome and liver disease and reducing hepatotoxicity of other drugs taken by patients 科赛普特治疗学股份有限公司 2025-01-14 CN claimed
US-20240245659-A1 Methods of Treating Cushing's Syndrome and Liver Disorders, and of Reducing Liver Toxicity of Other Drugs Administered to a Patient CORCEPT THERAPEUTICS INCORPORATED (US) 2024-07-25 US claimed
CN-110891562-B Lithium salts of N-substituted glycine compounds and uses thereof 心悦生医股份有限公司 2024-07-16 CN claimed
US-20230414575-A1 MK2 ACTIVATING COMPOUNDS FOR USE IN TREATING VASCULAR LEAK AND ENDOTHELIAL BARRIER DISORDERS AKTTYVA THERAPEUTICS INC (US) 2023-12-28 US claimed
US-20230414702-A1 COMPOUNDS AND PHARMACEUTICAL USE THEREOF IN THE TREATMENT OF CANCER PEPKON SAS (FR) 2023-12-28 US claimed
US-20230372312-A1 Methods of Treating Cushing's syndrome and Liver Disorders, and of Reducing Liver Toxicity of Other Drugs Administered to a Patient CORCEPT THERAPEUTICS INCORPORATED (US) 2023-11-23 US claimed
WO-2023225282-A1 METHODS OF TREATING CUSHING'S SYNDROME AND LIVER DISORDERS, AND OF REDUCING LIVER TOXICITY OF OTHER DRUGS ADMINISTERED TO A PATIENT CORCEPT THERAPEUTICS INCORPORATED (US) 2023-11-23 WO claimed
US-20230346820-A1 METHODS AND COMPOSITIONS FOR THE TREATMENT OF SARS-COV-2 THE SCRIPPS RESEARCH INSTITUTE 2023-11-02 US claimed
EP-4244341-A2 MK2 ACTIVATING COMPOUNDS FOR USE IN TREATING VASCULAR LEAK AND ENDOTHELIAL BARRIER DISORDERS Akttyva Therapeutics, Inc. (US) 2023-09-20 EP claimed
WO-2002039879-A2 TREATMENT OF ANTI-DEPRESSION DRUG-INDUCED SEXUAL DYSFUNCTION WITH APOMORPHINE TAP PHARMACEUTICAL PRODUCTS, INC. (US) 2002-05-23 WO claimed
CN-1335772-A Use of apomorphine in the manufacture of a medicament for the treatment of organic erectile dysfunction in males ABBOTT LAB (US) 2002-02-13 CN claimed
EP-1140094-A1 USE OF APOMORPHINE IN THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF ORGANIC ERECTILE DYSFUNCTION IN MALES ABBOTT LABORATORIES (US) 2001-10-10 EP claimed
US-6291471-B1 Use of apomorphine for the treatment of organic erectile dysfunction in males ABB HOLDINGS, INC. 2001-09-18 US claimed
CN-1294519-A Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient INPHARMA SA (CH) 2001-05-09 CN claimed
EP-1073470-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2001-02-07 EP claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 WO claimed
WO-2000035457-A1 USE OF APOMORPHINE IN THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF ORGANIC ERECTILE DYSFUNCTION IN MALES ABBOTT LABORATORIES (US) 2000-06-22 WO claimed
EP-0179583-A1 A system for enhancing the water dissolution rate and solubility of poorly soluble drugs MERCK & CO. INC. (US) 1986-04-30 EP claimed
EP-0147780-A2 Drug delivery device MERCK & CO. INC. (US) 1985-07-10 EP claimed